Pristiq generics — when can they launch?
Pristiq (Desvenlafaxine Succinate) · Pfizer · 3 active US patents · 0 expired
Where Pristiq sits in the generic timeline
Imminent generic cliff: earliest active US patent for Pristiq expires in 2027 (~1 year from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Composition of Matter — 3 patents
Sample patent estate
Showing 3 of 3 active US patents. View full estate on the Pristiq drug page →
-
This patent protects derivatives of venlafaxine, including methods of preparing and using them to treat various diseases and disorders.USPTO title: Derivatives of venlafaxine and methods of preparing and using the same
-
This patent protects derivatives of venlafaxine, including methods of preparing and using them to treat various diseases and disorders.USPTO title: Derivatives of venlafaxine and methods of preparing and using the same
-
This patent protects derivatives of venlafaxine, including methods of preparing and using them to treat various diseases and disorders.USPTO title: Derivatives of venlafaxine and methods of preparing and using the same
Sources
- FDA Orange Book — patents listed against Pristiq (NDA filed 2008)
- Pristiq drug profile — full patent estate, indications, clinical trials, pricing
- Pfizer patent portfolio
- Patent cliff 2027 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Pristiq — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →